Loading clinical trials...
Loading clinical trials...
This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy. The objectives of th...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Boehringer Ingelheim
NCT04099290 · Head and Neck Neoplasm, Carcinoma, Squamous Cell
NCT06998069 · Head and Neck Neoplasms
NCT06912087 · Head and Neck Neoplasms, Carcinoma, Squamous Cell, and more
NCT06303180 · Hearing Loss, Head and Neck Neoplasms, and more
NCT07158164 · Colorectal Neoplasms, Breast Neoplasms, and more
1200.43.00113 Boehringer Ingelheim Investigational Site
Harvey, Illinois
1200.43.00106 Boehringer Ingelheim Investigational Site
Peoria, Illinois
1200.43.00110 Boehringer Ingelheim Investigational Site
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions